An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
about
Omega 3 fatty acids for prevention and treatment of cardiovascular diseaseOmega-3-acid Ethyl Esters (Lovaza) For Severe HypertriglyceridemiaThe clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaNovel therapies for the prevention of strokeA review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levelsThe metabolic syndromeOmega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.Triglycerides and HDL cholesterol: stars or second leads in diabetes?Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Statins and their interactions with other lipid-modifying medications: safety issues in the elderlyFish oil and the management of hypertriglyceridemia.Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.Diabetes Health, Residence & Metabolism in Asians: the DHRMA study, research into foods from the Indian subcontinent - a blinded, randomised, placebo controlled trialUses and benefits of omega-3 ethyl esters in patients with cardiovascular disease.Functional foods and nutraceuticals in the primary prevention of cardiovascular diseases.Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.Fish oil for the treatment of cardiovascular disease.Dietary polyunsaturated fatty acids and anorexia nervosa: is there a link?Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation.Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl estersEfficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial.Complementary and alternative therapies for the management of dyslipidemia.Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.Dietary approaches that delay age-related diseases.Combination therapy in the management of mixed dyslipidaemia.Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.Dispelling the myths about omega-3 fatty acids.Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy.Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations.Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy.Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease.Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.The metabolic syndrome: definition, global impact, and pathophysiology.Support of drug therapy using functional foods and dietary supplements: focus on statin therapy.A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.Functional food ingredients as adjunctive therapies to pharmacotherapy for treating disorders of metabolic syndrome.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
P2860
Q24245810-26BF4DEF-210C-4A5E-A2B3-2565DCEB33D7Q24658510-DC97EAA3-F9CF-4D2A-95E2-1C60A97C2090Q26738554-4B7E618F-93E2-47BE-A70E-994D6B5EDA13Q28210724-B2C63351-8AB6-409A-8540-62EC7524B040Q28219488-5B5F1854-996F-452B-9749-607988902575Q33569142-06B5A710-DE94-4A07-AF28-41ACFC55F095Q33594958-703C1E99-E704-4F8D-9B38-F5ADE03A6F69Q33610637-F9242C92-A983-4F39-B4F7-22940A8F80F3Q33620368-00C08F33-CED3-4D81-904C-D7885B852F3FQ33776194-C1E0F00B-D2EE-4768-89A8-6F2BD628D8BCQ33949348-8DEA7D6D-7606-4B57-9DE4-5EF65D334972Q34016763-34D6536B-41DA-4B06-974E-E7B248DACC0EQ34042886-5F0826B3-C7EC-4253-B9BF-56D2832AC09AQ34089508-67229B9B-EBBE-46D6-972A-494CAC57673CQ34418028-6B666E9A-9AAE-4686-A339-345D79F166ECQ34638162-4B121CB7-2CF3-49CC-BDFE-A129912EABA0Q35107668-BDA64528-2DA8-4FC4-80F3-92AFAE1897B7Q35552231-9FD7FD30-0484-49FC-828B-2C6FA5E23E93Q35746297-705D1D8B-7D43-4D8F-82EF-90918A49C6D5Q36250306-CF6E7692-E947-483B-AD5B-3F8261DCA246Q36310496-1CCADBD4-07D3-4947-BD6C-9BDED929414FQ36350869-EEF03AEE-5CD7-4842-A5D3-F9D169E1EA1BQ36626326-27E054E5-93B9-4102-B303-077085FB0043Q36802569-AF0E04F4-8E19-499B-970A-67BAF1F5140CQ37019058-3F6681CE-3427-4968-BDD2-136FD0E250C8Q37103948-64F435F9-0F8C-470F-B1F2-9DF5CEE73C19Q37104877-2B9FAC70-7B3A-4D63-8BFF-F89DABD64786Q37142087-9C673C29-6D7A-465E-962D-5E013735158EQ37226404-6B12A1BE-CDA6-46FD-8E4E-E492BD1A2228Q37250773-90A3C87E-1AF6-4905-A90A-1DC806CF919EQ37257327-B70B1543-DC55-40B5-A861-242598882684Q37367669-F1B35A6A-C6B4-46B6-8E28-87C79DE4B6F2Q37376934-1DCE1747-31A0-4EC6-B221-170C9F19CC2BQ37388065-C81FFED4-D8CC-41EC-8A9C-563EDE71BE54Q37458941-76427742-E97A-4D74-85EF-0414F95F522CQ37617790-8344CA15-F21C-4B4D-B14C-73EA40E041A0Q37701534-3CAE25FA-9A5F-4CC1-BC83-22DCC1823A7CQ37740352-E7852CB4-34C3-44D5-8C82-CC576691B41DQ37756954-5604EA83-4370-48C2-8047-90F3CE13ABC4Q37772510-686DC98F-FCC7-499F-AE68-77273031697D
P2860
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@ast
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@en
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@nl
type
label
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@ast
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@en
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@nl
prefLabel
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@ast
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@en
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
An omega-3 polyunsaturated fat ...... rsisting hypertriglyceridaemia
@en
P2093
D Bhatnagar
M I Mackness
P N Durrington
P2860
P3181
P356
10.1136/HEART.85.5.544
P407
P577
2001-05-01T00:00:00Z